HER2 targeting in esophagogastric cancer: Redefining the landscape and breaking barriers Review
| Authors: | Cytryn, S. L.; Janjigian, Y. Y. |
| Review Title: | HER2 targeting in esophagogastric cancer: Redefining the landscape and breaking barriers |
| Abstract: | HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of care for more than a decade. However, with the incorporation of dual HER2 and PD-1 blockade as well as the advent of a new, potent antibody-drug conjugate, trastuzumab deruxtecan, there have been 2 new FDA approvals for this patient population within the past 2 years. Consequently, the management and landscape of HER2-positive EGC is rapidly changing and increasingly optimistic. |
| Keywords: | epidermal growth factor receptor 2; receptor, erbb-2; trastuzumab; stomach neoplasms; esophagus tumor; esophageal neoplasms; esophageal cancer; stomach tumor; gastric cancer; antibody conjugate; immunoconjugates; humans; human; her2 therapy |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 21 |
| Issue: | 4 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2023-04-01 |
| Start Page: | 423 |
| End Page: | 429 |
| Language: | English |
| DOI: | 10.6004/jnccn.2023.7010 |
| PUBMED: | 37015333 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 May 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work